NRX Pharmaceuticals Inc.-CW22NRXPWPreferred / convertible
13F holders, Q3 2025 (September 30)4holders +1
2new positions
1sold out
$1.46avg. 13F price*
At the end of Q3 2025, 4 institutions reported holding NRX Pharmaceuticals Inc.-CW22 (NRXPW) in their 13F filings, up 1 from Q2 2025. 2 opened new positions and 1 sold out. The largest holders were B Group, Inc. ($4.5M), Susquehanna International Group, LLP ($3K) and Wolverine Asset Management LLC ($2K).
- Company
- NRX Pharmaceuticals Inc.-CW22
- CUSIP
- 629444118
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $4.5M |
| Exits | 1 | $3K |
All 13F filers, Q2 2025 → Q3 2025: 3,042,167 shares bought and 40,447 shares sold, net +3,001,720 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| B Group, Inc. | — | New | 3,000,000 | $4.5M |
| Susquehanna International Group, LLP | — | New | 42,167 | $3K |
| Wolverine Asset Management LLC | — | No change | 21,778 | $2K |
| UBS Group AG | — | Reduce -98.8% | 18 | $1 |
"% of holder's portfolio" is NRXPW's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc.-CW22 the manager owns.